0001638599-20-000919.txt : 20201124 0001638599-20-000919.hdr.sgml : 20201124 20201124162426 ACCESSION NUMBER: 0001638599-20-000919 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20201120 FILED AS OF DATE: 20201124 DATE AS OF CHANGE: 20201124 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: LaBelle Curt H CENTRAL INDEX KEY: 0001396235 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38365 FILM NUMBER: 201344475 MAIL ADDRESS: STREET 1: C/O INVESTOR GROWTH CAPITAL, INC. STREET 2: 630 FIFTH AVENUE, SUITE 1965 CITY: NEW YORK STATE: NY ZIP: 10011 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: EYENOVIA, INC. CENTRAL INDEX KEY: 0001682639 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 471178401 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 295 MADISON AVENUE, STREET 2: SUITE 2400 CITY: NEW YORK STATE: NY ZIP: 10017 BUSINESS PHONE: 813-766-9539 MAIL ADDRESS: STREET 1: 295 MADISON AVENUE, STREET 2: SUITE 2400 CITY: NEW YORK STATE: NY ZIP: 10017 4 1 doc4_6919.xml PRIMARY DOCUMENT X0306 4 2020-11-20 0 0001682639 EYENOVIA, INC. EYEN 0001396235 LaBelle Curt H C/O EYENOVIA, INC. 295 MADISON AVENUE, SUITE 2400 NEW YORK NY 10017 1 0 0 0 Common Stock, par value $.0001 2020-11-20 4 J 0 453333 0.00 D 0 I By PME Investor Services Eyenovia, LLC Common Stock, par value $.0001 35273 D Common Stock, par value $.0001 606667 I By Private Medical Equity, Inc. Stock Option (right to buy) 1.24 2015-03-02 2025-03-02 Common Stock 40000 40000 D Stock Option (right to buy) 1.95 2027-07-07 Common Stock 133334 133334 D Stock Option (right to buy) 3.11 2029-08-16 Common Stock 45256 45256 D Stock Option (right to buy) 3.43 2030-09-11 Common Stock 9820 9820 D Stock Option (right to buy) 1.24 2015-03-23 2025-03-23 Common Stock 140000 140000 I By Private Medical Equity, Inc. On November 20, 2020, PME Investor Services Eyenovia, LLC, of which the reporting person is a manager, distributed its holdings of the Issuer's common stock in-kind and on a pro rata basis to its members. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. The option became exercisable as to 3,704 shares on August 7, 2017 and becomes exercisable in equal 3,704 share amounts on each of the 35 one-month anniversaries thereafter. One-third of the option became exercisable on August 16, 2020 and the remaining shares underlying the option become exercisable in equal increments on each of the 24 one-month anniversaries thereafter. The option becomes exercisable on the earlier of September 11, 2021 or the date of the Issuer's 2021 annual meeting at stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors and acceleration upon change in control. /s/ S. Halle Vakani, Attorney-in-Fact 2020-11-24